NanoString Technologies Inc. Announces Oral Study Presentation of the Prosigna™ Assay in Postmenopausal Node-Positive Breast Cancer at the 2013 Annual American Society of Clinical Oncology
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology (ASCO) Meeting on Sunday, June 2.
Help employers find you! Check out all the jobs and post your resume.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology (ASCO) Meeting on Sunday, June 2.
Help employers find you! Check out all the jobs and post your resume.